Equity Incentive Plans (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 20, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 16, 2022
Options
Outstanding balance at the beginning of the period (in shares)				8,525,618
Granted (in shares)				3,900,000
Forfeited (in shares)				(492,915)
Outstanding balance at the end of the period (in shares)		11,932,703		11,932,703		8,525,618
Options exercisable at the end of the period (in shares)		6,907,653		6,907,653
Options vested and expected to vest at end of period (in shares)		11,932,703		11,932,703
Weighted Average Exercise Price Per Share
Outstanding balance at the beginning of the period (in dollars per share)				$ 4.48
Granted (in dollars per share)				1.51
Forfeited (in dollars per share)				2.17
Outstanding balance at the end of the period (in dollars per share)		$ 3.60		3.60		$ 4.48
Exercisable at the end of the period (in dollars per share)		5.01		5.01
Options vested and expected to vest at end of the period (in dollars per share)		$ 3.60		$ 3.60
Weighted Average Remaining Life in Years
Outstanding balance				7 years 7 months 24 days		7 years 6 months 29 days
Options exercisable at end of period				6 years 4 months 20 days
Options vested and expected to vest at end of the period				7 years 7 months 24 days
Aggregate Intrinsic Value
Outstanding balance		$ 1		$ 1
Options vested and expected to vest at end of the period		$ 1		$ 1
Assumptions used to determine grant-date fair value
Expected Volatility				82.70%	66.94%
Weighted average risk-free interest rate				3.06%	0.81%
Expected dividend yield				0.00%	0.00%
Expected term (in years)				6 years 5 months 23 days	6 years 9 months 25 days
Options unvested at end of period (in dollars per share)		$ 1.10	$ 1.37	$ 1.10	$ 1.37
Expiration period				10 years
unrecognized compensation cost related to non-vested stock options		$ 5,493		$ 5,493
Weighted average period for recognition of compensation cost				2 years 3 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Outstanding at end(in dollars per share)		$ 1.10	$ 1.37	$ 1.10	$ 1.37
Minimum
Assumptions used to determine grant-date fair value
Vesting period				3 years
Maximum
Assumptions used to determine grant-date fair value
Vesting period				4 years
2016 Plan
Assumptions used to determine grant-date fair value
Annual increase in authorized shares (as a percent)	4.00%
Number of options or stock awards available for grant under the Plan		5,382,799		5,382,799
2022 Plan
Assumptions used to determine grant-date fair value
Number of options or stock awards available for grant under the Plan							7,500,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock-based compensation expense		$ 1,253	$ 1,003	$ 3,723	$ 2,748
Options to purchase common stock | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock-based compensation expense		634	477	1,805	1,220
Options to purchase common stock | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock-based compensation expense		619	$ 526	$ 1,918	$ 1,528
Restricted stock units to purchase common stock
Assumptions used to determine grant-date fair value
Weighted average period for recognition of compensation cost				2 years 2 months 19 days
Aggregate grant fair value				$ 6,777
unrecognized compensation costs related to RSUs granted to employees		$ 4,463		$ 4,463
Restricted stock units to purchase common stock | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded				2,650,000	275,000
Restricted stock units to purchase common stock | 2016 Plan
Assumptions used to determine grant-date fair value
Options unvested at end of period (in dollars per share)		$ 1.89		$ 1.89		$ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at the beginning				935,606
Awarded				2,650,000
Outstanding at the end		3,585,606		3,585,606		935,606
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Outstanding at beginning( in dollars per share)				$ 1.76
Awarded (in dollars per share)				1.93
Outstanding at end(in dollars per share)		$ 1.89		$ 1.89		$ 1.76